Abstract
Objective To investigate the association between human gut antibiotic resistome and the progression of type 2 diabetes (T2D) in a large cohort study.
Design The present study included 1210 participants from the Guangzhou Nutrition and Health Study. We depicted the landscape of human gut antibiotic resistome with shotgun metagenomic data and examined its association with T2D and cardiometabolic traits. The co-occurrence network analysis was used to explore the associations between T2D-related ARGs and gut microbial species. We also examined the associations between gut antibiotic resistome features and fecal metabolome.
Results There was a significant overall shift in gut antibiotic resistome structure among healthy, prediabetes and T2D groups (p = 0.004). We found that larger ARG diversity was associated with a higher risk of T2D (all p < 0.05). Based on the association found between resistomes and T2D, we developed diabetes ARG score and demonstrated its creative use as a new predictor for T2D progression manifested by the change of insulin resistance. Further network analysis showed the co-occurrence association between T2D-related ARGs and gut microbial species, which indicated the potential bacterial hosts of these ARG biomarkers. Resistome-metabolome co-analysis suggests a potential link of ARGs with fecal metabolites, which may reflect the host-microbial metabolic adaptation.
Conclusion Our data depict the landscape of gut antibiotic resistome diversity and composition and uncover a close relationship between human gut antibiotic resistome and T2D progression.
Significance of this study
What is already known about this subject?
What is already known about this subject?
Human gut is the key reservoir of microbiota harboring both commensal and pathogenic bacteria.
Growing evidence has revealed that the gut microbiota composition was associated with type 2 diabetes (T2D).
Prospective cohort studies showed that self-reported long-term use of antibiotics was associated with higher T2D risk.
What are the new findings?
What are the new findings?
There was a significant overall shift in gut antibiotic resistome structure among healthy, prediabetes and T2D groups.
We found for the first time that higher gut ARG diversity was associated with a higher risk of T2D.
We constructed a diabetes ARG score (DAS) using the identified T2D related ARGs, it was positively associated with glycemic traits.
Longitudinal validation analysis confirmed that the DAS was associated with T2D progression, characterized by the change of insulin resistance.
How might it impact on clinical practice in the foreseeable future?
How might it impact on clinical practice in the foreseeable future?
Our findings support a recommendation to avoid the abuse of antibiotics, and the identified antibiotic resistome markers could also be served as potential intervention target in future.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03179657
Funding Statement
This work was supported by the National Natural Science Foundation of China (82073529, 51908467, 81903316, 81773416), Zhejiang Ten-thousand Talents Program (2019R52039), Westlake Multidisciplinary Research Initiative Center (MRIC20200301), The National Key Research and Development Program of China (2018YFE0110500) and the 5010 Program for Clinical Research (2007032) of the Sun Yat-sen University (Guangzhou, China). The funders were not involved in the study design, implementation, the analysis or the interpretation of data.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Ethics Committee of the School of Public Health at Sun Yat-sen University (2018048) and Ethics Committee of Westlake University (20190114ZJS0003).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The raw data of metagenomic sequencing is available in the CNSA (https://db.cngb.org/cnsa/) of CNGBdb at accession number CNP0001510. Other data sets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.
Abbreviations
- ARG
- antibiotic resistance genes;
- T2D
- type 2 diabetes;
- rRNA
- ribosomal RNA;
- GNHS
- Guangzhou Nutrition and Health Study;
- FFQ
- food-frequency questionnaire;
- PCoA
- principal coordinate analysis;
- PERMANOVA
- permutational multivariate analysis of variance;
- TC
- total cholesterol;
- HDL
- high-density lipoprotein;
- LDL
- low-density lipoprotein;
- HbA1c
- glycated haemoglobin;
- DAS
- Diabetes ARG score;
- MLS
- Macrolide-Lincosamide-Streptogramin;
- HOMA-IR
- homeostatic model assessment of insulin resistance
